PATENT

Docket No.: 320185.00109 Customer No. 27160



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Leland SHAPIRO

Serial No. 09/518,076

Filed: March 3, 2000

For: INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS

FOR TREATMENT OF HERPES VIRUSES

REQUEST FOR CORRECTED FILING RECEIPT

Group Art Unit: 1653

Examiner: Unknown

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Applicant's attorneys have received an official Filing Receipt in the above-identified application in which the domestic priority data was omitted. The priority data is indicated on the attached copy of the Filing Receipt in RED ink and highlighted.

Issuance of a Corrected Filing Receipt, corrected as shown above, is accordingly respectfully requested.

If there are any fees necessary to enter this request, the Commissioner is authorized to charge the fee to our Deposit Account No. 50-1710.

Respectfully submitted,

Gilberto M. Villacorta, Ph.D. Registration No. 34,038

Gianna Julian Arnold Registration No. 36,358

Patent Administrator KATTEN MUCHIN ZAVIS ROSENMAN 525 West Monroe Street, Suite 1600 Chicago, Illinois 60661-3963

Fax: (312) 906-1021 (202) 625-3500

Date: August 1, 2002




United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

IND CLAIMS FILING DATE GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO **DRAWINGS** TOT CLAIMS APPLICATION NUMBER 971 114232.109 2 39 13 09/518.076 03/03/2000 1653

27160 PATENT ADMINSTRATOR KATTEN MUCHIN ZAVIS **SUITE 1600** 525 WEST MONROE STREET CHICAGO, IL 60661



CONFIRMATION NO. 5437 CORRECTED FILING RECEIPT OC000000007451115*

Date Mailed: 02/08/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If y u received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Leland Shapiro, Denver, CO;

Domestic Priority data as claimed by applicant This applie claims benefit of 60/123,167 03/05/99
Freign Applications 60/153, 942 09/15/99 F reign Applications

If Required, Foreign Filing License Granted 05/11/2000

Projected Publication Date: Not Applicable, filed prior to November 29,2000

N n-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses

Preliminary Class

514

LICENSE FOR FOREIGN FILING UNDER Titl 35, United States Code, S ction 184 Titl 37, Cod f Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
Washington, D.C. 20231
www.uspto.gov

CONFIRMATION NO. 5437

DID Data Sheet					
SERIAL NUMBER 03/03/2000 RULE		CLASS 514		GROUP ART UNIT 1653	
APPLICANTS Leland Shapiro,	Denver, CO;				
THIS APPLN CL AND CLAIMS B	A ************************************	0/123,167 03/05/1999 2 09/15/1999 ****			
IF REQUIRED, FOREI ** 05/11/2000	IGN FILING LICENSE	GRANTED ** SMALI	ENTITY **		
Foreign Priority claimed 35 USC 119 (a-d) conditions met Verified and Acknowledged Exa	yes no Met aft Allowance	STATE OI COUNTRY CO		TOTAL CLAIMS 39	INDEPENDENT CLAIMS 13

TITLE

ADDRESS 27160

Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses

	FEES: Authority has been given in Paper No to charge/credit DEPOSIT ACCOUNT No for following:
RECEIVED	No to charge/credit DEPOSIT ACCOUNT

	1.16 Fees (Filing)
☐ time	1.17 Fees (Processing Ext. of
	1.18 Fees (Issue)
	Other
	Credit

All Fees

RECEIVED

RIGITS 2002

RECHCENTER 1800/2900